A new predictor of mortality in hemodialysis patients; Tenascin-C

Ulusoy, Şükrü; Özkan, Gülsüm; Menteşe, Ahmet; Güvercin, Beyhan; Karahan, Süleyman Caner; Yavuz, Adnan; Altay, Diler Us

doi:10.1016/j.lfs.2015.09.011

Cited by 10 publications

(10 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of included studies were conducted in Asia (Japan, China, Taiwan; 30 in total). Among the remaining 18 studies: ten were undertaken in Europe (France, Italy, Macedonia, Sweden, Germany, Montenegro, The Netherlands, Spain and Turkey) [ 20 , 22 , 26 , 27 , 30 , 34 , 42 , 46 , 57 , 60 ], three in the United States [ 18 , 21 , 36 ], one in Australia and New Zealand [ 39 ], one in South Africa [ 17 ], and two included more than one geographical region [ 29 , 41 ].…”

Section: Resultsmentioning

confidence: 99%

“…23 out of the 48 included studies reported a higher cardiovascular mortality rate in men than women, with risk estimates ranging from 1.16 to 3.51 (Tables 2 and 3 ) [ 18 – 20 , 25 , 30 , 35 , 37 , 38 , 42 , 45 , 55 , 57 , 58 , 60 – 62 ]. However, 18 of the 48 studies showed that men had a lower risk of cardiovascular mortality compared to women, with risk estimates ranging from 0.29 to 0.93 (Tables 2 and 3 ) [ 23 , 24 , 34 , 39 , 44 , 46 , 47 , 49 , 53 , 54 , 59 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Relationship between sex and cardiovascular mortality in chronic kidney disease: A systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a significant health challenge associated with high cardiovascular mortality risk. Historically, cardiovascular mortality risk has been found to higher in men than women in the general population. However, recent research has highlighted that this risk may be similar or even higher in women than men in the CKD population. To address the inconclusive and inconsistent evidence regarding this relationship between sex and cardiovascular mortality within CKD patients, a systematic review and meta-analysis of articles published between January 2004 and October 2020 using PubMed/Medline, EMBASE, Scopus and Cochrane databases was performed. Forty-eight studies were included that reported cardiovascular mortality among adult men relative to women with 95% confidence intervals (CI) or provided sufficient data to calculate risk estimates (RE). Random effects meta-analysis of reported and calculated estimates revealed that male sex was associated with elevated cardiovascular mortality in CKD patients (RE 1.13, CI 1.03–1.25). Subsequent subgroup analyses indicated higher risk in men in studies based in the USA and in men receiving haemodialysis or with non-dialysis-dependent CKD. Though men showed overall higher cardiovascular mortality risk than women, the increased risk was marginal, and appropriate risk awareness is necessary for both sexes with CKD. Further research is needed to understand the impact of treatment modality and geographical distribution on sex differences in cardiovascular mortality in CKD.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Relationship between sex and cardiovascular mortality in chronic kidney disease: A systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In addition, anti-tenascin-C antibodies coupled to radioisotopes might be useful to image tissues and tumors of high tenascin-C gene expression (reviewed in Gu et al, 2015;Jacobson et al, 2015;Orend et al, 2014;Spenle et al, 2015b). Detection of high protein levels of tenascin-C within pathological tissues as well body fluids could be of diagnostic value and might provide a means to earlier detect associated conditions, including heart disease, fibrosis, pre-eclempsia, rheumatoid arthritis, systemic lupus erythematosus and cancer (Orak et al, 2016;Orend et al, 2014;Schwenzer et al, 2015;Ulusoy et al, 2015, Franz et al, 2015, Imanaka-Yoshida, 2012. Finally, the high levels of tenascin-C found in breast milk of HIV-infected mothers can potentially be exploited in a HIVprevention strategy 'designed by nature' as their breast-fed infants are protected from contracting HIV (Fouda et al, 2013).…”

Section: Tenascin-c In Tissuesmentioning

confidence: 99%

Tenascin-C at a glance

Midwood

Chiquet

Tucker

et al. 2016

Journal of Cell Science

358

357

View full text Add to dashboard Cite

Tenascin-C (TNC) is a hexameric, multimodular extracellular matrix protein with several molecular forms that are created through alternative splicing and protein modifications. It is highly conserved amongst vertebrates, and molecular phylogeny indicates that it evolved before fibronectin. Tenascin-C has many extracellular binding partners, including matrix components, soluble factors and pathogens; it also influences cell phenotype directly through interactions with cell surface receptors. Tenascin-C protein synthesis is tightly regulated, with widespread protein distribution in embryonic tissues, but restricted distribution of tenascin-C in adult tissues. Tenascin-C is also expressed de novo during wound healing or in pathological conditions, including chronic inflammation and cancer. First described as a modulator of cell adhesion, tenascin-C also directs a plethora of cell signaling and gene expression programs by shaping mechanical and biochemical cues within the cellular microenvironment. Exploitment of the pathological expression and function of tenascin-C is emerging as a promising strategy to develop new diagnostic, therapeutic and bioengineering tools. In this Cell Science at a Glance article and the accompanying poster we provide a succinct and comprehensive overview of the structural and functional features of tenascin-C and its potential roles in developing embryos and under pathological conditions.

show abstract

“…In our study, higher TN-C concentrations were not associated with diabetic nephropathy. In high-risk haemodialysed patients (38% with type 2 diabetes), serum TN-C concentrations were found to predict all-cause-and CV-mortality [28]. In the latter study, high TN-C concentrations were associated with high blood glucose concentrations, and the authors attributed this relationship to the microvascular complications related to increased expression of TN-C (among other ECM components) that has been reported in the retina of individuals with diabetes [26].…”

Section: Discussionmentioning

confidence: 84%

“…Recently, a big-data approach in >8400 individuals with dysglycaemia identified TN-C, among other biomarkers, as an independent determinant of CV outcomes or death [11,12]. In individuals with chronic kidney disease (CKD;~40% with type 2 diabetes), higher serum TN-C levels were significantly associated with CV-associated morbidity and/or death [27,28]. The association between TN-C and CV events in a population of purely diabetic individuals remains to be demonstrated.…”

Section: Introductionmentioning

confidence: 99%

Serum tenascin-C is independently associated with increased major adverse cardiovascular events and death in individuals with type 2 diabetes: a French prospective cohort

et al. 2020

View full text Add to dashboard Cite

Aims/hypothesis Tenascin-C (TN-C) is an extracellular matrix glycoprotein highly expressed in inflammatory and cardiovascular (CV) diseases. Serum TN-C has not yet been specifically studied in individuals with type 2 diabetes, a condition associated with chronic low-grade inflammation and increased CV disease risk. In this study, we hypothesised that elevated serum TN-C at enrolment in participants with type 2 diabetes would be associated with increased risk of death and major adverse CV events (MACE) during follow-up. Methods We used a prospective, monocentric cohort of consecutive type 2 diabetes participants (the SURDIAGENE [SUivi Rénal, DIAbète de type 2 et GENEtique] cohort) with all-cause death as a primary endpoint and MACE (CV death, non-fatal myocardial infarction or stroke) as a secondary endpoint. We used a proportional hazard model after adjustment for traditional risk factors and the relative integrated discrimination improvement (rIDI) to assess the incremental predictive value of TN-C for these risk factors. Results We monitored 1321 individuals (58% men, mean age 64 ± 11 years) for a median of 89 months. During follow-up, 442 individuals died and 497 had MACE. Multivariate Cox analysis showed that serum TN-C concentrations were associated with an increased risk of death (HR per 1 SD: 1.27 [95% CI 1.17, 1.38]; p < 0.0001) and MACE (HR per 1 SD: 1.23 [95% CI 1.13, 1.34]; p < 0.0001). Using TN-C concentrations on top of traditional risk factors, prediction of the risk of all-cause death (rIDI: 8.2%; p = 0.0006) and MACE (rIDI: 6.7%; p = 0.0014) improved significantly, but modestly. Conclusions/interpretation In individuals with type 2 diabetes, increased serum TN-C concentrations were independently associated with death and MACE. Therefore, including TN-C as a prognostic biomarker could improve risk stratification in these individuals.

show abstract

A new predictor of mortality in hemodialysis patients; Tenascin-C

Cited by 10 publications

References 25 publications

Relationship between sex and cardiovascular mortality in chronic kidney disease: A systematic review and meta-analysis

Relationship between sex and cardiovascular mortality in chronic kidney disease: A systematic review and meta-analysis

Tenascin-C at a glance

Serum tenascin-C is independently associated with increased major adverse cardiovascular events and death in individuals with type 2 diabetes: a French prospective cohort

Contact Info

Product

Resources

About